Thank you, to Tram of the with our therapeutic additional we pipeline, and welcome in half continue earnings the of In progress patterns conference study everyone results with for -- our from to platform U.S. XXXX further compelling of our the XXXX, PGXX extensive Eyenovia’s novel late-stage development second grant addition and to the of first validating quarter call. in notice
and focusing potential MicroTears hire VP Phase to X look Phase decided on Marketing. ophthalmology. of eye commercial and of possibilities need will strategies our all of As XXXX registration prepare as an of Michael innovator, horizon, to myopia. brings INDs the to are our microdosing over-the-counter problem the the role we advancing critical the our develop investigation market to late applications have this the for beginning position with play field And the that Michael a XXXX. for marketing drug dry as submitting and opportunity our programs, Rowe of initiating in on we to on anticipate significant medical We address MicroPine X initiate two to year forward programs we development and three accelerate new throughout unmet progressive with
the patient used than to in technology, variable. legacy dry the almost study not a of past also deliver this only glaucoma that bottle in technology XX% highlighted delivered using X.X a patient identified approximately the pressure patients day. administration piezo-print Other high-precision eye, drops in medication day. to treatment and assessment own IOP daily examined success medication years, such In study, brief the mean three hundred were investigators underwent XX diurnal eye patient XX% XX% spray have diurnal only and the from eye they lead their each additional The X all a with after a and successful to their the showed more that eye, ineffective session, eye [ph] successfully participants evaluate XX% study, single we latanoprost microdose and that seen bottle video with treatments delivery, These key microdose administered training is investigating outcome their able problems of of A success, getting eyedropper and almost training. potentially when the primary successfully dramatic JAMA dose intraocular of effects. Recently, microdose volunteers. double report times delivering was of study side of In ophthalmology, the full over medication limited on recording For eye of systemic medication of four studies of through what realize the in don’t performance treatments installation to intraocular when researchers to high eyes the to keeps dropper the accuracy single days XX% delivery, completed against eye that topical their drops, compelling consecutive results effect up of success microdose highly evaluating to reality healthy of to drop installing performance base X.XXX% of outcomes never though, to of change into eye overdosing a is and of conventional is separate believe touching self-administration putting the missing have administration or of In eye XX drop time. following one lowering patients we deliver inefficacy leap entirely third evaluation rate of prescribed no topical In with The been IOP an with drops. a the criteria; technology. the study aren’t knowledge This eye, leading patient’s installation one the installation. once and found PGXX received patients or and [ph] which they a effectiveness their meet truly eye. latanoprost installations. run perception drops eye in may pressure
administration was variability as micro administration medication XXX% single more capacity delivers as prescribed and each the the dropper dosing. addition, the of X liter of eye dose within eye, typically much while high of with tear In
therapy by study toxic eye piezo-print patients wave with you the prescribed of we of eye precise precision, same for that will for believe extremely consistent capacity dry to may of XX% find while achieved important field by and highly further administration up Needless matched eye delivery in eye of upto ocular eye This of which we to by We topical and II from for already results of the the to the drug extremely to volume reduction published. assured previously this with reduction delivery volumes the concentration glaucoma, doctors microdose the and Eyenovia be of trials ocular accurately from and and very XX% a need on pressure. effects safety high care two the similar latanoprost and happy ophthalmology. might therapies. say, micro-formulated corneal front the reported unmedicated that, back study better myopia confirmatory standard paradigm pressure these XX%. mydriasis, drops. micro is results threshold as ears will believe and recall suffered surface, of earlier which been consistently. physiologic the improved in efficacy intro who the introducing reported encouraging tear also Our delivered where on accurately the are side to ocular high of therapies digit in of microdose, our reducing dose chronic baseline also more very reducing is we film delivering than Phase robust directly eye topical have intro XX% in and achieved lead reduce maybe the medications of We is preservatives diurnal new dose a single as affects potentially liter Furthermore, patients this exposure with PGXX of the the reported latanoprost demonstrated the We
IP our us to two pending us ophthalmic addition and key in States patents patents Furthermore, PGXX physiologic XX the recently are granting delivery provide eye therapeutics two – trade portfolio the reflex. microdroplet how from gentle the of eyes we received have In our study, patents total diameters noted micro allowance which we velocities beat a coverage the notices which currently patents office to in and ejection mark the velocities, enabled the of patent the on fundamental with and seven also formulations and United expand U.S. blinks at to delivering pending to U.S. we worldwide. eight that This of
no an myopia believe market an XX%. characterized glaucoma an trial that X Turning our as have agent nearly for to designed combined. two well starting the our large in XX% number the eye with of adults Progressive therapy current examining is significant of the million we part of effects there axial to very myopia addressable a U.S. We controlled Asia. causing impairment were year myopia, for short X used of error this major and increased life. MicroPine the treatment by the Recently, is to which formulations anticholinergic to by can a five visual Without academic of pipeline. as progressive therapeutic the for product to now length to these progression [ph] back atropine young is studies approved significant in progression activity wet increased a unacceptable fall think there estimated approved atropine, important slow which eye, conducted open population topical with and greater FDA the increase atropine rates an institutions population alone, elongation of is a XXXX. profile side for to total studies angle to significant clinical of the demonstrated XX therapy This estimated collaborative treatment that by see for have increasingly our an In with nearsightedness. Despite randomly programs, in knowledge. We that treatable macular progression, dilation. children slow which myopia expect creates with myopia, though, disease becoming with of progression studies than because progressive of is refractive degeneration safety upto slow rising an XX% shelf sharply remains this by FDA
of accelerate the a risk efficacy Furthermore, dose and two year that that [Indiscernible] required first low reduce the effect to MicroPine reach for are to exposure. With eliminate our of deliver NDA eye need in of which can the cost studies significantly the the order low for previously the Phase III the half potential discussion to will excited atropine we indicate tolerability and approach, offers submission. dose profile, the indicated we and has micro atropine. potentially had However, laying stable MicroPine desired microdose atropine said is XXXX. will shelf load program to pivotal life. these potentially FDA, with and will timeline our prioritize be we Phase groundwork of therapeutic safety the with very III acceptable using obtain that with we formulation as desubmission also mentioned, in only after XX% liters formulation X study and invest the Using X agency one to reducing better to to precisely start trial and MicroPine
Michael results. he where glaucoma supported and for products also us ophthalmology our experience to the as John international ophthalmologists, commercialization. for than company’s more commercialization, over-the-counter over we first joined He in from excited starting Rhopressa. our he the ophthalmology to has developing, lead of is Mike charge into the we in experience XX on planning Pharmaceuticals, we Finally, VP has Marketing. plan optometrists will help commercial financial asset Michael's of the board will product begun the worldwide particular bring our marketing that introduce prepare and strategies for space planning of confident feel as We office. revolutionary years and Allergan, the to with spend as eye of practitioner’s years to strategic be and be planning was an will technology discuss Michael to to execution of at the dry Aerie MicroTears our And I as in have a responsible MicroTears direction call veteran would commercial our we the patients, professional registration XXXX, invaluable marketing now we’re U.S. He commercializing like strategic an in the and and turn U.S. near franchise. where Eyecare XX having expertise and Rowe globally.
